Kymera Therapeutics Presents New Preclinical Data for KT-579
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the presentation of new preclinical data for KT-579, a first-in-class, oral IRF5 degrader.
KT-579 demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies.
- KT-579 is a potent, selective, oral degrader of IRF5.
- Phase 1 testing for KT-579 is expected to begin in early 2026.
No direct quote available in the given text.
Author's summary: Kymera Therapeutics presents new preclinical data for KT-579.
More News
- Jensen Ackles back on 'Tracker' 3.2 to amp up the suspense
- Biopic reintroduces female revolutionary hero - BusinessWorld Online
- Deandre Ayton claims Los Angeles Lakers superstars ‘troll him’ to get him going
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Budget jitters see construction forecasts plummet
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- 2 US Navy aircraft crash in South China Sea
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- Elon Musk could step down if Tesla pay plan is rejected
- Wallingford deli asks for help to keep feeding people in need